Moderna finalizes strategic partnership with uk government

Facility to enable access to domestically manufactured mrna respiratory vaccines, pending regulatory assessment and licensure the ten-year strategic partnership is expected to provide the uk public with response capabilities to ensure future preparedness in light of the covid-19 pandemic moderna is expanding its presence in the uk through investments in r&d activities and capabilities cambridge, ma / accesswire / december 21, 2022 / moderna, inc . (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced the finalization of a strategic partnership with the uk government to establish a state-of-the-art mrna research, development, and manufacturing facility in the uk.
MRNA Ratings Summary
MRNA Quant Ranking